Roivant Sciences (ROIV) Total Non-Current Liabilities (2021 - 2026)
Roivant Sciences (ROIV) posted Total Non-Current Liabilities of $11.9 million for Q1 2026, down 99.71% on a QoQ basis from $4.0 billion in Q4 2025, and down 35.5% year-over-year from $18.4 million in Q1 2025.
Roivant Sciences (ROIV) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Roivant Sciences' Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $11.9 million for Q1 2026.
- Quarterly Total Non-Current Liabilities fell 35.5% year-over-year to $11.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.9 million (down 35.5% YoY) and the FY2026 annual result came in at $11.9 million, down 35.5% from the prior year.
- Total Non-Current Liabilities was $11.9 million for Q1 2026 at Roivant Sciences, down from $4.0 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $4.0 billion in Q4 2025 and bottomed at $11.9 million in Q1 2026.
- A 5-year average of $748.9 million and a median of $668.6 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities tumbled 97.99% — and 2025, when it jumped 225.93%.
- Roivant Sciences' Total Non-Current Liabilities stood at $754.3 million in 2022, then decreased by 11.36% to $668.6 million in 2023, then soared by 85.04% to $1.2 billion in 2024, then soared by 225.93% to $4.0 billion in 2025, then slumped by 99.71% to $11.9 million in 2026.
- Business Quant data shows ROIV's Total Non-Current Liabilities at $11.9 million in Q1 2026, $4.0 billion in Q4 2025, and $257.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Roivant Sciences | 24.35 Bn | 25.12 Bn | - | 11.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.88 Mn |
| Dec 31, 2025 | 4.03 Bn |
| Sep 30, 2025 | 256.97 Mn |
| Jun 30, 2025 | 216.47 Mn |
| Mar 31, 2025 | 18.42 Mn |
| Dec 31, 2024 | 1.24 Bn |
| Sep 30, 2024 | 625.69 Mn |
| Jun 30, 2024 | 599.50 Mn |
| Mar 31, 2024 | 15.36 Mn |
| Dec 31, 2023 | 668.64 Mn |
| Sep 30, 2023 | 734.74 Mn |
| Jun 30, 2023 | 785.61 Mn |
| Mar 31, 2023 | 764.99 Mn |
| Dec 31, 2022 | 754.35 Mn |
| Sep 30, 2022 | 692.28 Mn |
| Jun 30, 2022 | 814.36 Mn |
| Mar 31, 2022 | 501.77 Mn |
| Dec 31, 2021 | 521.45 Mn |
| Sep 30, 2021 | 643.82 Mn |
| Jun 30, 2021 | 466.68 Mn |